Author:
Pilkinton Sophie,Hollingsworth T.J.,Jerkins Brian,M. Jablonski Monica
Abstract
Glaucoma is a multifactorial, polygenetic disease with a shared outcome of loss of retinal ganglion cells and their axons, which ultimately results in blindness. The most common risk factor of this disease is elevated intraocular pressure (IOP), although many glaucoma patients have IOPs within the normal physiological range. Throughout disease progression, glial cells in the optic nerve head respond to glaucomatous changes, resulting in glial scar formation as a reaction to injury. This chapter overviews glaucoma as it affects humans and the quest to generate animal models of glaucoma so that we can better understand the pathophysiology of this disease and develop targeted therapies to slow or reverse glaucomatous damage. This chapter then reviews treatment modalities of glaucoma. Revealed herein is the lack of non-IOP-related modalities in the treatment of glaucoma. This finding supports the use of animal models in understanding the development of glaucoma pathophysiology and treatments.
Reference95 articles.
1. Li H, M.M., Jablonski MM., Relevance of miRNAs to Eye Disease. miRNAs and Human Diseases, 2012: p. 179-196
2. Tham, Y.-C., et al., Global Prevalence of Glaucoma and Projections of Glaucoma Burden through 2040: A Systematic Review and Meta-Analysis. Ophthalmology, 2014. 121(11): p. 2081-2090
3. Kingman, S., Glaucoma is second leading cause of blindness globally. Bulletin of the World Health Organization, 2004. 82: p. 887-8
4. Anthony Khawaja MA(Cantab), M.B., MRCOphth Primary Open-Angle Glaucoma - Eyewiki. 2019 [cited 2021 February 13, 2021]; Available from: https://eyewiki.aao.org/Primary_Open-Angle_Glaucoma
5. Soto, I. and G. Howell, The Complex Role of Neuroinflammation in Glaucoma. Cold Spring Harbor Perspectives in Medicine, 2014. 4